Novacyt exists to help protect public health from the world’s invisible threat of infectious diseases.

By providing rapid and accurate diagnostic solutions, in the right place at the right time, we enable healthcare professionals, governments, individuals and organisations to make appropriate and informed decisions. We strive to address areas of high unmet need in infectious diseases.

We are constantly innovating to develop new products and improve existing solutions to provide the highest quality diagnostics that enable healthcare professionals to deliver optimal care.

Our global surveillance expertise and relationships with the scientific community also help us to provide solutions to emerging or anticipated healthcare threats from around the world. Research and insights inform our activity and allow us to position ourselves as first responders in the global fight against infectious diseases.

We are a team of dedicated, passionate industry-leading experts, working from customers insights and evaluation to research and development, to manufacturing, to commercialisation.

We offer a comprehensive and developing portfolio of high-end products, backed by a global network of proven supply & delivery services. This ensures our end-to-end commitment to quality.

Supporting communities and wider society

At Novacyt, we believe in contributing to communities where we operate, and we have made donations to various charities and schools in the areas our offices are located. Following the transformational financial performance of Novacyt in 2020, a charity steering committee was created made up from a number of key employees within the group tasked with identifying schools and charities in need of support particularly following the COVID-19 pandemic. In 2021 a sum of £500,000 was dedicated to supporting a total of 25 schools and 50 charities throughout the year. We assisted projects looking to support critically ill children and adults, the homeless, old age pensioners and war veterans.

To support efforts to tackle the COVID-19 pandemic in Africa, Novacyt continues to work in partnership with non-governmental organisations to provide testing across the globe.

The Novacyt group is proud to play a part in supporting local communities and is truly humbled by the impact our charitable donations continue to make under the leadership of our charity steering committee on a yearly basis moving forwards.

James McCarthy

Chief Financial Officer and Acting Chief Executive Officer

Paul Oladimeji

Group Head of R&D

Bryan Close

Chief Operations Officer

David Franks

Chief Human Resources Officer

James Wakefield

Non-executive Director & Chairman of the Board

James McCarthy

Chief Financial Officer and Acting Chief Executive Officer

Juliet Thompson

Non-executive Director

Dr Andrew Heath

Non-executive Director

Dr. Edwin Snape

Non-executive Director

Jean-Pierre Crinelli

Non-executive Director

Quality Policy

Within the Novacyt Group, we are committed to Quality as a fundamental part of all our business activities and strive to meet and exceed external and internal customer expectations. As a learning organisation we will continuously drive innovation, improvement and excellence for all our products and services whilst meeting all regulatory requirements for the markets we serve.

To support this, we have established this Quality Policy and have the following Quality Statements:

  • To implement and maintain a Quality Management System that complies with the requirements laid down in the IVD Directive (98/79/EC), ISO 9001, ISO 13485 and other regulations as required to support business activities
  • To monitor and measure the performance of both the products we sell, and the systems and processes we operate to identify and implement continuous improvements
  • To ensure that the importance of Quality is communicated to all employees throughout the business through regular information updates, and that employees are trained and supported to deliver high quality goods, products and services
  • To involve all employees in owning and improving the Quality Management System to the benefit of customers, employees and other interested parties
  • To place Quality as a fundamental cornerstone of annual business strategic planning

This Quality Policy will be reviewed annually for continuing suitability.